Biopharma developing complement and inflammation drugs
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 24,670 | $469,717 | 0.0% |
| Steve Cohen / Point72 | 75 | New buy | 274,093 | $5,218,731 | 0.0% |
| Ancora | 42 | Trimmed -17% | 140,625 | $2,677,500 | 0.1% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.